CSat Investment Advisory L.P. Increases Stake in Humana Inc (NYSE:HUM)

Share on StockTwits

CSat Investment Advisory L.P. grew its position in Humana Inc (NYSE:HUM) by 3.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,138 shares of the insurance provider’s stock after acquiring an additional 144 shares during the quarter. CSat Investment Advisory L.P.’s holdings in Humana were worth $1,098,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in HUM. PointState Capital LP purchased a new position in Humana in the 2nd quarter worth about $180,507,000. Marshall Wace North America L.P. increased its position in Humana by 6,921.1% during the 2nd quarter. Marshall Wace North America L.P. now owns 536,275 shares of the insurance provider’s stock valued at $142,273,000 after purchasing an additional 528,637 shares during the period. Point72 Asset Management L.P. purchased a new position in Humana during the 2nd quarter valued at about $115,680,000. Diamond Hill Capital Management Inc. purchased a new position in Humana during the 2nd quarter valued at about $86,802,000. Finally, Ceredex Value Advisors LLC increased its position in Humana by 31.8% during the 1st quarter. Ceredex Value Advisors LLC now owns 957,094 shares of the insurance provider’s stock valued at $255,111,000 after purchasing an additional 230,671 shares during the period. 92.77% of the stock is currently owned by institutional investors and hedge funds.

NYSE HUM traded down $1.13 on Friday, hitting $277.28. 768,203 shares of the company’s stock traded hands, compared to its average volume of 875,071. The company has a current ratio of 1.75, a quick ratio of 1.75 and a debt-to-equity ratio of 0.37. Humana Inc has a 1-year low of $225.65 and a 1-year high of $355.88. The firm’s 50-day moving average price is $286.44 and its two-hundred day moving average price is $268.51. The firm has a market capitalization of $36.90 billion, a PE ratio of 19.06, a P/E/G ratio of 1.18 and a beta of 0.84.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.05 EPS for the quarter, beating the consensus estimate of $5.24 by $0.81. Humana had a net margin of 4.13% and a return on equity of 22.47%. The business had revenue of $16.25 billion during the quarter, compared to analysts’ expectations of $15.88 billion. During the same period in the previous year, the business posted $3.96 EPS. The business’s quarterly revenue was up 13.9% compared to the same quarter last year. On average, research analysts anticipate that Humana Inc will post 17.67 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.79%. The ex-dividend date of this dividend is Friday, September 27th. Humana’s dividend payout ratio (DPR) is 15.12%.

HUM has been the topic of a number of research reports. JPMorgan Chase & Co. raised their target price on shares of Humana from $288.00 to $322.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. Cantor Fitzgerald upgraded shares of Humana from a “neutral” rating to an “overweight” rating and raised their price target for the company from $300.00 to $345.00 in a report on Monday, August 12th. ValuEngine cut shares of Humana from a “hold” rating to a “sell” rating in a report on Wednesday, September 11th. UBS Group raised their price target on shares of Humana from $266.00 to $317.00 and gave the company a “neutral” rating in a report on Thursday, August 1st. Finally, Morgan Stanley raised their price target on shares of Humana from $315.00 to $342.00 and gave the company an “overweight” rating in a report on Friday, August 23rd. Two research analysts have rated the stock with a sell rating, four have given a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $339.74.

In other news, insider Brian P. Leclaire sold 7,239 shares of Humana stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $289.70, for a total transaction of $2,097,138.30. Following the completion of the transaction, the insider now directly owns 12,994 shares of the company’s stock, valued at approximately $3,764,361.80. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.54% of the stock is owned by insiders.

Humana Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Story: Momentum Investing

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

SOTHERLY HOTELS/SH SH  Upgraded by Zacks Investment Research to Hold
SOTHERLY HOTELS/SH SH Upgraded by Zacks Investment Research to Hold
Solaredge Technologies  Lowered to Hold at Zacks Investment Research
Solaredge Technologies Lowered to Hold at Zacks Investment Research
Resonant  Upgraded to “Hold” at Zacks Investment Research
Resonant Upgraded to “Hold” at Zacks Investment Research
Portola Pharmaceuticals  PT Lowered to $44.00
Portola Pharmaceuticals PT Lowered to $44.00
UltraNote Coin Reaches Market Cap of $13,486.00
UltraNote Coin Reaches Market Cap of $13,486.00
FS KKR Capital Corp  Receives $7.63 Consensus PT from Analysts
FS KKR Capital Corp Receives $7.63 Consensus PT from Analysts


© 2006-2019 Ticker Report